So, you may have heard that the DEA rescheduled CBD. While CBD was never actually explicitly scheduled on the Controlled Substances Act also known as the CSA, it has been considered “scheduled” by many due to its association with cannabis.

Cannabis as you probably know is still classified as a schedule 1 substance according to the CSA. This is alongside illicit, deadly street drugs such as heroin, LSD, and ecstasy.

The Announcement Details

The recent announcement that you may have heard about was pertaining to a new pharmaceutical CBD based epilepsy drug called Epidiolex.

This drug which was recently approved by the FDA was classified as a schedule 5 substance on the CSA by the DEA in late September.

This places the pharmaceutical cannabis-derived drug in the same classification as Robitussin and Lyrica, while the natural plant is still considered to be of no medical value per the CSA.

The 411 You Need to Know

Here is what you need to know about this recent move by the DEA.

  • This classification does not pertain to all CBD products, only Epidiolex. That is until more FDA-approved drugs are approved that fit into the details of the rescheduling order which is detailed below.
  • The rescheduling order “places FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinols in schedule V.” This means that the drug must be made with CBD derived from cannabis, not hemp. It also means that the drug must contain less than .1% of THC and have the approval of the FDA to fit into this classification/scheduling.
  • This change does not affect the legality of other CBD derived products whether they are from hemp or cannabis.
  • This does not provide protection for companies within the United States that are selling CBD products, only protection for GW Pharmaceuticals for the Epidiolex offering.

This change will allow a pharmaceutical company to make millions in profits each year due to the $32,500 price tag attached to the annual use of the drug.

This is quite unfortunate considering that the natural plant that can provide the same effects for a much lower cost is still demonized and will cost thousands of people jail time and much more this year alone.

  Posted: Thursday, October 11th, 12:00pm a month ago
Profile PictureWritten By: Ashley Priest

Ashley is a freelance cannabis writer and the co-owner of CannaLance. Her passion for sharing education and truth surrounding cannabis stems from a personal loss. Ashley has always had an elevated relationship with cannabis but it wasn't until 2015 that she turned that passion and relationship into a career as a cannabis writer.

Roottie keeps me up to date on all things cannabis. From new uses for CBD to opportunities that affect my business, Roottie is my source. Roottie provides informative and entertaining information that is up to date and accessible. -Karla Watson - Tact HR Services

Break It Up